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In recent years there has been a rapid growth of interest in exploring the relationship between
nutritional therapies and the maintenance of cognitive function in adulthood. Emerging evidence
reveals an increasingly complex picture with respect to the benefits of various food constituents
on learning, memory and psychomotor function in adults. However, to date, there has been little
consensus in human studies on the range of cognitive domains to be tested or the particular tests
to be employed. To illustrate the potential difficulties that this poses, we conducted a systematic
review of existing human adult randomised controlled trial (RCT) studies that have investigated
the effects of 24 d to 36 months of supplementation with flavonoids and micronutrients on
cognitive performance. There were thirty-nine studies employing a total of 121 different
cognitive tasks that met the criteria for inclusion. Results showed that less than half of these
studies reported positive effects of treatment, with some important cognitive domains either
under-represented or not explored at all. Although there was some evidence of sensitivity to
nutritional supplementation in a number of domains (for example, executive function, spatial
working memory), interpretation is currently difficult given the prevailing ‘scattergun approach’
for selecting cognitive tests. Specifically, the practice means that it is often difficult to distinguish
between a boundary condition for a particular nutrient and a lack of task sensitivity. We argue that
for significant future progress to be made, researchers need to pay much closer attention to
existing human RCT and animal data, as well as to more basic issues surrounding task sensitivity,
statistical power and type I error.
Cognitive tests: Micronutrients: Phytochemicals: Adult randomised controlled trials
Introduction
As the number of individuals over the age of 60 years is
expected to double between 2000 and 2050(1), the projected
incidence of age-related neurodegenerative diseases and
associated health care costs is also set to rise significantly.
In a recent report commissioned by the Alzheimer’s
Society, the current annual cost of dementia in the UK
alone was estimated to be about £17·03 billion(2), with the
total worldwide cost estimated to be US$315·4 billion
annually(3). Moreover, given that individuals aged
65 years can now expect to live for at least another
20 years, there is an urgent need to identify means of
mitigating age-related changes in healthy older adults. Diet
is crucial in this respect as it is thought to reduce the impact
of age-related cognitive decline, for instance, by combating
oxidative stress, reducing LDL-cholesterol, and modulating
neurological mechanisms such as cell-signalling pathways.
Over the last decade or so a significant, albeit mixed,
body of evidence regarding the effects of diet on cognition
has accumulated from human and animal work. For
instance, in longitudinal and human observational studies,
vitamin E intake has been associated with reduced age-
related cognitive decline through its antioxidant proper-
ties(4), and poorer memory performance has been linked to
lower levels of serum vitamin E per unit of cholesterol(5).
Evidence from The Rotterdam Study has shown an
association between higher plasma folate and better
cognitive function, in particular for tests measuring
psychomotor processing speed(6), episodic memory and
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale Cognitive Subscale; category A, studies employing best designs and
clear results; category B, studies with some weaknesses but no major problems; category C, studies showing significant methological and
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verbal ability(7). In the PAQUID (Personnes Age´es QUID,
loosely translated to ‘What about the elderly?’) study, older
adults with the highest dietary flavonoid intake showed
significantly lower cognitive decline over 10 years than
those with the lowest intake(8). Studies using animal models
have also demonstrated that certain groups of flavonoids
may slow and even reverse the effects of ageing and
dementia(9 – 11). For example, memory deficits may be
prevented by the consumption of foods rich in anthocyanins,
a flavonoid subgroup(12 – 16).
While still an emerging area, an examination of the
available human randomised controlled trial (RCT)
literature reveals rather more variable evidence for the
beneficial effects of diet on cognition. For example, in a
systematic review of B vitamin and antioxidant supplement
studies, Jia et al. (17) found very little evidence for cognitive
benefits from taking antioxidant supplements or B vitamins.
A similar story is shown for flavonoid studies(18), with
reports of both significant(19 – 23) and non-significant(24 – 29)
effects of supplementation.
Developing a better understanding of the conditions
under which particular nutrients do or do not derive
cognitive benefits represents a key challenge for research.
However, one major problem facing researchers aiming to
do this is that there is currently little consensus across
studies in terms of either the cognitive domains to be
explored or the specific tests to be used. Thus it is hard to
determine whether a failure to reproduce a previously
reported effect has established an important boundary
condition for that nutrient (for example, supplementation
with X not effective for population Y) or, alternatively, is a
reflection of the idiosyncrasies of the respective tasks
employed across the two studies. For example, although it is
often assumed that all tests of working memory perform-
ance reflect common mechanisms or processes, it is quite
possible that different tests measure partially separate
cognitive capacities(30) and that performance dissociates
across different tests. Indeed, Waters & Caplan (2003)(31)
reported only moderate correlations between a series of
seven different working memory measures. Thus simply
assuming a one-to-one correspondence between two
different cognitive measures purporting to measure the
same domain (for example, working memory) is ill-advised.
In the present paper we aim to establish the extent of this
practice, as well as make recommendations for future
studies.
Cognitive domains and associated brain regions
For the purposes of structuring the present review we now
briefly outline the major taxonomies within human
cognition. Importantly, attempts to characterise the effects
of dietary nutrients on human cognition need to utilise a
wide range of tasks to fully assess cognitive ability. In so
doing, two points should be borne in mind. Firstly, although
a particular task might be identified as having a primary
neuropsychological focus such as ‘executive function’ or
‘episodic memory’, such measures are not ‘task pure’(32).
For example, a range of processes may support a nominally
‘executive’ task such as memory, processing speed and
motor function. Secondly, in terms of the underlying brain
regions supporting cognitive performance, it is important
to recognise that any task is likely to recruit multiple neural
regions. For example, functional neuroimaging studies have
revealed activations in the prefrontal cortex, medial and
lateral parietal cortex, as well as hippocampal/medial
temporal lobe activations during episodic memory retrie-
val(33). A thorough understanding of the brain regions
underpinning performance on particular cognitive tests is
important, especially when attempting to relate findings
from human studies to animal work. We return to this point
in the Discussion.
Executive function
Executive function is a complex term used to describe a
number of distinct, specifiable ‘control’ functions that are
distinguishable from processing speed, memory, and motor
functions. Examples of executive functions include ‘switch-
ing’ or ‘shifting’ (for example, alternating between
behaviours or information sources), ‘inhibition’ (the ability
to suppress automatic and habitual responses or beha-
viours), ‘updating’ (the ability to discard and replace
information(34,35)), ‘sustained attention’ (requiring sus-
tained concentration and monitoring skills(35,36)), ‘strategic
memory search’ (conscious, controlled retrieval of struc-
tured information(32,35 – 37)), and ‘planning’ (the ability to
deal with novel information, generate goals and make
decisions on a suitable course of action(32,35)). Neuroima-
ging studies suggest that the prefrontal cortex and striatum
interact to perform specific executive functions(38), and that
distinct brain regions are recruited for different executive
functions. For instance, the left inferior frontal gyrus in
the prefrontal cortex is recruited in verbal fluency tasks(39),
whereas the right inferior frontal gyrus shows
greater activation in tasks measuring both shifting and
inhibition(38).
Working memory
All of the above executive functions are dependent on
‘working memory’, a psychological construct used to
describe a hypothetical system for the temporary mainten-
ance and manipulation of speech-based and/or visuospatial
information, requiring the control of attentional
resources(32). Functional neuroimaging work shows that
working memory is not a unitary or dedicated system, and is
not localised to a single brain region(40). D’Esposito
described working memory as ‘an emergent property of
functional interactions between the PFC [prefrontal cortex]
and the rest of the brain’ (p. 769)(40), and evidence suggests
that the network of brain regions recruited for the active
maintenance of task-relevant information will depend on the
type of information being maintained(40,41).
Memory
A number of key distinctions can be drawn between
different types of memory. Specifically, researchers
frequently distinguish between short-term memory (retrie-
val occurs within 30 s of stimulus presentation) v. long-term
memory (retrieval occurs after 30 s); explicit memory
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(consciously and intentionally retrieved) v. implicit memory
(unconsciously retrieved); episodic (memory for events) v.
semantic (memory for meaning); retrospective (memory for
past events) v. prospective memory (remembering to
perform actions in the future); memory for skills (procedural
memory) v. memory for facts (declarative memory); and
verbal memory v. visual or visuospatial memory.
As might be expected, a wide range of brain regions are
thought to be involved in supporting these various forms of
memory. For instance, activation of left-lateralised posterior
temporal regions, the supramarginal gyrus, dorsolateral
premotor cortex and Broca’s area have been associated with
short-term memory(42), in contrast to activation of bilateral
ventrolateral prefrontal regions and dorsolateral prefrontal
regions during encoding and recognition in long-term
episodic memory(43). In terms of the neural substrate of
explicit and implicit memory tasks(44), explicit memory has
been linked to left frontal, and bilateral hippocampal,
parahippocampal and parietal activation(45), whereas
implicit memory is primarily associated with reduced left
fusiform gyrus and bilateral frontal and occipital
activity(46,47). The hippocampus, parahippocampus and
parietal areas are typically implicated in spatial memory
tasks(48), whereas the anterior prefrontal cortex has been
shown to be actively involved in prospective memory
tasks(49).
Motor function, perception and intelligence quotient
Motor function may be measured with or without a
cognitive component, and encompasses a range of measures
from psychomotor processing speed to planning of move-
ment. Voluntary movement is controlled by the basal
ganglia system, which includes the striatum and substantia
nigra, by enabling required motor mechanisms and
inhibiting competing mechanisms(50). Various brain regions
are thought to be involved during motor skill acquisition:
prefrontal regions are recruited initially, with a subsequent
shift to posterior regions, for example, premotor, posterior
parietal and cerebellar cortex structures, as the task becomes
more automatic(51).
Visual perception relies on visual acuity, field of view and
contrast sensitivity, abilities that are reduced with age(52,53)
and which underpin any cognitive function with a visual
component. Visual perception is associated with a wide
range of brain regions in neuroimaging studies, namely the
striate cortex and other occipital areas, parietal, temporal
and prefrontal regions(54).
Intelligence tasks may be sub-divided into crystallised
intelligence (measuring acquired knowledge) and fluid
intelligence (measuring non-verbal ability, problem-solving
and pattern recognition independently of acquired knowl-
edge)(55). General intelligence, or Spearman’s g, is
associated most closely with fluid intelligence and
activation of the lateral frontal(56) or prefrontal cortex and
parietal areas(57).
Research aims and questions
The primary aim of the present paper is to review the
cognitive methods used in existing RCT studies that have
explored the effects of nutrition on human cognition, with a
view to identifying domains (for example, executive
function, episodic memory) and individual tasks within
those domains (for example, category fluency task, common
objects recall task) that have shown greatest sensitivity to
chronic supplementation (for example, supplementation
of a nutrient over a number of days, weeks or months, as
opposed to an acute intake of a nutrient on a single
experimental day). A related aim is to catalogue the
cognitive tasks used in existing chronic RCT studies within
a single framework enabling researchers to better choose
suitable tasks, as well as identify potential gaps in terms of
the domains measured.
It should be noted here that significant outcomes for
cognitive testing in dietary intervention studies rely on two
things: (1) the potential for cognitive change as a result of
direct dietary intervention with respect to dose and duration
in the cognitive domain or cognitive aspect being measured
and (2) cognitive methodologies sensitive enough to
measure such cognitive change. The most important
consideration in setting up a suitable framework for
measuring human cognitive function in nutritional research
is to determine methods that are sensitive to dietary changes
and repeatable over time, are simple to interpret, and
specific to cognitive domains. In this respect, brief measures
such as the Mini-Mental State Examination (MMSE)(58) and
the Alzheimer’s Disease Assessment Scale Cognitive
Subscale (ADAS-Cog)(59) are suitable for cognitive screen-
ing of dementia and mild cognitive impairment, a term
generally used to describe the level of cognitive impairment
found in the intermediate stage between normal ageing and
fully developed dementia(60). Both the MMSE and the
ADAS-Cog consist of items covering a broad range of
cognitive functions: orientation, attention and calculation,
memory, language, and motor skills, but they cannot truly be
said to measure ‘global cognitive function’, as the individual
test items do not measure the full range of cognitive
functions. The term ‘general cognitive function’ is therefore
preferred here.
In terms of examining changes in cognitive performance
over time, the MMSE and ADAS-Cog may be useful for the
measurement of widespread, gross cognitive changes in
longitudinal studies(8); in Alzheimer’s disease research,
where the fastest rate of deterioration over time is likely to
be seen, the MMSE has shown an overall progression rate of
0·24 points per month, although this was moderated by
education duration, sex, disease incidence and drug
therapy(61). However, such measures are unlikely to be
sensitive to smaller changes over shorter time periods in
healthier individuals at pre-dementia stages, and will indeed
show ceiling effects in young and/or cognitively healthy
adult populations.
Overall we address four main questions:
(1) What proportion of chronic dietary interventions has
reported significant benefits to cognition and in which
domains?
(2) How much consistency is there across studies in terms
of cognitive domains measured and tasks employed?
(3) Are there any cognitive domains that are under-
represented in existing intervention studies?
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(4) What are the implications for future chronic dietary
intervention studies?
Methods
A search of five databases (PUBMED, Web of Know-
ledge, PsychINFO, CINAHL and the Cochrane Central
Register of Controlled Trials) was carried out for
micronutrient or phytochemical adult human randomised
controlled intervention trials exploring cognitive function
as the primary or secondary outcome. The following
search terms were used:
Cognitive tasks: cogniti*, executive function, switching,
shifting, updating, inhibition, vigilance, attention, memory,
episodic, semantic, implicit, explicit, spatial, visuospatial,
prospective, declarative, procedural, processing speed,
psychomotor, reaction time, accuracy.
(1) Nutrient: vitamin*, thiamin*, riboflavin, niacin,
nicotinamide, pantothenic, pyridox*, biotin, cobala-
min*, folic acid, folate, ascorbic, tocopherol, iron,
copper, zinc, magnesium, manganese, selenium,
flavan*, flavon*, isoflavone, caroten*.
(2) Population sample: human adult [not] adolescent,
child, infant, maternal, rat, mouse, mice, rodent, dog,
monkey.
(3) Experimental design: randomi*, controlled trial, RCT.
(4) Type of article: journal article, peer-reviewed.
All studies identified through the literature search were
evaluated according to the eligibility criteria by one
reviewer and independently verified by a second reviewer.
The search was limited to the previous 10 years (for
example, 1 January 1999 to 31 August 2009).
Chronic studies that specifically focused on the cognitive
effects of the target nutrients, both single and combined,
were included. Studies exploring phytochemicals adminis-
tered in extract rather than whole-food form (for example,
Ginkgo biloba) were included. Studies on populations
suffering from age-related cognitive impairment or
dementia were included, except in the case of traumatic
head injury or specific neurological disorders, whose
findings may not be generalisable to a normal human
adult population.
Acute interventions, non-randomised studies, RCT with
sample sizes of less than twenty participants (or less than ten
for cross-over designs), and studies that did not include a
proper baseline, or control and/or placebo group were
excluded. Studies using whole foods or treatments
combined only with macronutrients or drug therapy were
also excluded, as were drug therapy studies using
micronutrients as a placebo control. As the present review
is focusing on micronutrient or phytochemical strategies for
the attenuation and prevention of cognitive decline
throughout the adult lifespan, cognitive development studies
(for example, maternal, infant and child) were excluded. As
we were primarily interested in comparing uniquely human,
language-based cognitive paradigms across studies, animal
studies were excluded. Also excluded were studies of
specific hospital-based patient groups (for example, CHD,
stroke or diabetes), as were studies comparing pre- and
post-operative cognitive performance. The literature search
and screening process is shown in Fig. 1.
Outcomes were changes in cognitive performance. The
first author categorised the tasks and the second author
resolved any inconsistencies encountered during classifi-
cation. Tasks were initially categorised by their primary
neuropsychological focus, which was determined by the
descriptions provided in the selected papers. Where
disagreement occurred, the authors used the task descrip-
tions cited in the majority of the included studies and
checked these, where possible, against Lezak et al. (62), a
comprehensive sourcebook of neuropsychological
assessment.
All included studies were rated using a three-category
quality assessment grading system (A, B, C), based on a
method successfully trialled elsewhere(63,64), to identify any
methodological shortcomings which might affect interpret-
ation of the results. Briefly, category A studies employ the
best designs, such that they are sufficiently powered with
less than 20 % drop-out, methods (double-blind, interven-
tion, comparator, outcome measures and statistical tests) are
appropriate, results are clearly reported and assessed as
valid. Category B studies may contain some weaknesses, but
show no major problems and are still considered valid.
Category C studies show significant methodological
difficulties which may invalidate results, with flawed
designs and analysis, missing information, greater than
20 % drop-out, randomisation issues (for example, unequal
between-group baseline scores), reporting discrepancies and
low power. Grading was carried out and agreed by the first
and second authors.
Studies were examined for cognitive outcome status in
order to see if the RCT was designed primarily to test
cognitive function, or if cognition was only a secondary
outcome measure, as this again may affect the validity of the
results. Cognitive outcome status was then designated as
‘primary’ or ‘secondary’ for all RCT.
Articles identified for possible
retrieval (n 1301)
Articles retrieved for further
evaluation (n 55)
Titles and abstracts screened:
articles not meeting inclusion
criteria identified, e.g. not human,
adult, chronic, micronutrient,
phytochemical, or RCT (n 1246)
Excluded articles (n 15):
Acute studies (n 1)
Whole food studies (n 3)
No baseline cognitive measure (n 4)
Nutrient used as placebo/control (n 2)
Micronutrient combined with drug therapy (n 1)
Micronutrient combined with macronutrients (n 1)
Sample size less than twenty participants (or ten
    participants for cross-over designs (n 2)
Patient group (n 2)
RCT included (n 39)
Fig. 1. Randomised controlled trial (RCT) literature search and
screening process.
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Results
Assessment of cognitive performance in existing studies
Thirty-nine studies met the inclusion criteria (see Table 1).
Five used multivitamins(65 – 69), and two of these also
included minerals(67,68). Ten studies examined vitamin B
treatments(70 – 79) and three looked at specific minerals:
Zn(80), Fe(81) and Cu(82). One trialled b-carotene with
vitamins C and E(83). Of the studies targeting indivi-
dual micronutrients or phytochemicals, twenty looked
at flavonoids(19 – 29,84 – 92). Twelve of these were
isoflavone RCT(19 – 22,24,25,27,28,84 – 86,89), six used G. biloba
extracts containing 24 or 25 % flavonoids and 6 %
terpenes(23,26,29,88,91,92), one used pine bark(90) and one
used cocoa flavanols(87). No other intervention met the
study criteria within the time frame of the review.
Fifteen studies (38 %) were graded as category C and
judged to contain significant bias that may invalidate the
results, mostly as a result of lack of any quantitative
cognitive screening, missing information and reporting
errors. Eighteen studies (46 %) were classed as category B
and judged to be susceptible to bias, but not sufficiently so
to invalidate the results. Only six studies (15 %) met the
more rigorous criteria for category A, as described earlier
(see Table 1). In the assessment of cognitive outcome status,
69 % of the RCT were found to be specifically designed
to measure cognitive function as the primary outcome
(see Table 1).
Only seventeen studies (44 %) reported benefits of
treatment on cognitive function in the expected direc-
tion(19 – 23,65,68,75,77,79,80,84,86,89 – 92), of which two were
graded as category A(77,80), seven were category
B(21 – 23,65,79,86,90) and the rest were category C. Twelve
of the seventeen RCT were flavonoid(19 – 23,84,86,88 – 92)
including seven isoflavone studies(19 – 22,84,86,89) and four
G. biloba interventions(23,88,91,92).
In evaluating these effects of treatment, there was found
to be considerable variability in the statistical rigour
employed in individual studies. Gleason et al. (20) reported
both positive and negative effects with a small sample size
of thirty, but did not appear to have accounted for the
possibility of type I error. Mix & Crews(88) reported a small
significant effect of treatment on a single outcome measure
using a one-tailed t test, a result unlikely to survive cut-off if
an arguably more appropriate two-tailed convention had
been employed. Additionally, both Casini et al. (84) and
Santos et al. (91) reported multiple t tests without any
apparent correction for type I error. Howes et al. (85) also
carried out a large number of tests on a small sample (n 30)
initially reporting a series of significant effects. However, as
an illustration of good practice, these disappeared after the
authors statistically accounted for type I error. Finally,
Stough et al. (92) provided no descriptive statistics at all,
making it impossible to evaluate the quality or rigour of
their experimental design and analysis.
Of the micronutrient studies, three vitamin B studies
reported some positive effects of treatment(75,77,79),
although Bryan et al. (79) also reported negative effects.
Two multivitamin interventions reported benefits(65,68), and
Maylor et al. (80) found both positive and negative effects of
Zn treatment on cognitive function.
Interestingly, four studies (10 %) showed only null and
negative effects of treatment on cognitive function: three
vitamin B studies(72,73,78) and one flavonoid intervention(27).
The vitamin B studies were carried out on older populations
and appear to have used t tests on multiple tasks with no
correction for type I error.
Of the thirty-nine studies included in the present review,
the size of study populations ranged from sixteen in a
functional magnetic resonance imaging cross-over study(87)
to 818(77). Seventeen studies had fewer than 100
participants, and five studies had forty participants or
less(20 – 22,26,85). Power calculations were carried out in only
four RCT, all researching vitamin B, with populations of
179 or more(71,72,75,76), but these were based largely on
expected changes in physiological rather than cognitive
markers. In other RCT, group size does not appear to have
been driven by effect sizes found in previous studies and
varies considerably across nutrient studies, for example
Pathansali et al. (73) with groups of twelve participants, and
Durga et al. (77) with groups of over 400.
Participant ages were highly variable, ranging from
18 years to over 80 years of age, with twenty-nine studies
(74 %) carried out on participants over the age of 50 years,
including nine studies specifically carried out on adults of
65 years or more. Three further RCT included young and
older adult populations(23,25,79), two more studies focused
on the 40–65 years age range(27,84), and five others were
conducted on 18- to 40-year-olds(21,26,81,87,92).
Single v. multiple cognitive domains
Among the thirty-nine RCT included in the present review, a
variety of approaches was used to measure cognitive
performance, mostly targeting multiple cognitive domains,
with the exception of a flavonoid brain imaging study which
used a single executive function ‘switching’ (or ‘shifting’)
task(87). Of the RCT testing multiple cognitive domains,
the majority examined a range of specific memory
processes and executive functions. The remaining RCT
targeted general cognition rather than any specific domain
(see Table 1).
Rationale for choice of cognitive tests
Twenty-one RCT based their choice of cognitive test(s)
on findings from previous studies. Eleven cited sensitivity
to the class of nutrient under investigation, such
as B vitamins, flavonoids, other type of dietary
manipulation, hormone replacement therapy or oestro-
gen(19,21,22,27,28,65,68,71,73,79,83). Seven studies instead used
tasks sensitive to ageing(29,77,85), brain disorders and
pharmacological interventions(23,76,80), or changes in func-
tional magnetic resonance imaging blood oxygenation
level-dependent (BOLD) signal(87). Three RCT selected
tasks from established computerised psychometric test
series: Ryan et al. (90) used the Cognitive Drug Researchw
battery(93); Murray-Kolb & Beard(81) the Cognitive Abilities
Test battery(94); and Mix & Crews(88) selected the Trail-
Making Test on the basis that it appeared to be ‘one of the
best measures of general cognitive functioning’ (p. 223)
according to Reitan(95). These tests were developed for use
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Table 1. Characteristics of included micronutrient and phytochemical human chronic randomised controlled trials
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Multivitamin Clarke et al.
(2003)(66)
128 56–89 Dementia, MCI,
older
adult
UK MCI, dementia
Dementia: DSM-IV
criteria and MMSE
12–26
MCI: Telephone Inter-
view for Cognitive
Status-Modified
, 27 (maximum 39)
Dementia drug therapy
and multivitamin
use allowed
Design: randomised
placebo-controlled
Outcome: secondary
Category: B
T1: 81 mg aspirin/d, 2 mg folic acid/d
and 1 mg vitamin B1/d
T2: 81 mg aspirin/d, 500 mg vitamin
E/d and 200 mg vitamin C/d
T3: placebo, 2 mg folic acid/d and
1 mg vitamin B1/d
T4: placebo, 500 mg vitamin E/d and
200 mg vitamin C/d
C: placebo (unspecified)
Duration: 12 weeks
General:
Telephone Interview for Cognitive
Status-Modified (screening)
MMSE (NS) (screening and
performance measure)
ADAS-Cog (NS)
Multivitamin Cockle et al.
(2000)(65)
127 60–83 Older adult UK n/a
Deficient in various
vitamins, particu-
larly B2, B6 and B12
Design: double-blind
randomised
placebo-controlled
Outcome: primary
Category: B
T: 3334 IU vitamin A/dk, 14 mg
vitamin B1/d, 16 mg vitamin B2/d,
180 mg niacin/d, 22 mg vitamin
B6/d, 2 mg biotin/d, 4 mg folic
acid/d, 0·03 mg vitamin B12/d,
600 mg vitamin C/d and 100 mg
vitamin E/d
C: placebo (rapeseed oil)
Duration: 24 weeks
IQ:
Alice Heim’s 4 and 5 Tests of General
Intelligence
National Adult Reading Test
General:
MMSE (NS)
Syndrom Kurtz Task (NS)
Memory:
Sternberg Memory Scanning Task (NS)
Word Scan Task (NS)
Psychomotor function/processing speed:
Choice Reaction Time (*P , 0·05)
Perception:
Critical Flicker Fusion (NS)
Multivitamin/
mineral
McNeill et al.
(2007)(67)
ITT: 910
(D/O: 133)
65 þ Older adult UK n/a Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: C
T: 800mg vitamin A/d, 60 mg
vitamin C/d, 5mg vitamin D/d,
10 mg vitamin E/d, 1·4 mg vita-
min B1/d, 1·6 mg vitamin B2/d,
18 mg niacin/d, 6 mg pantothenic
acid/d, 2 mg vitamin B6/d, 1mg
vitamin B1/d, 200mg folic acid/d,
14 mg Fe/d, 150mg iodine/d,
0·75 mg Cu/d, 15 mg Zn/d and
1 mg Mn/d
C: placebo (unspecified)
Duration: 12 months
Memory:
Digit Span Forward (NS)
Executive function/working memory:
Verbal Fluency (Initial Letter) (NS)
Multivitamin Wolters et al.
(2005)(69)
220
(D/O: 21/241)
60–91 Older adult,
female
Germany n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 150 mg vitamin C/d, 36 mg vitamin
E/d, 34 mg niacin/d, 16 mg pan-
tothenic acid/d, 9 mg b-caro-
tene/d, 3·4 mg vitamin B6/d,
3·2 mg vitamin B2/d, 2·4 mg
vitamin B1/d, 400mg folic acid/d,
200mg biotin/d, 60mg Se/d and
9mg vitamin B12/d (in soya oil)
C: placebo (soya oil)
Duration: 6 months
IQ:
KurzTest fu¨r Allgemeine Intelligenz (NS)
Psychomotor function/processing speed:
Symbol Search Test (NS)
Memory:
Berliner Amnesie Test (NS)
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Multivitamin Wouters-
Wesseling
etal. (2005)(68)
ITT: 101
(D/O: 34/101)
65 þ Older adult The Nether-
lands
T: 21 % MMSE # 23
C: 24 % MMSE ¼ 23
BMI , 25 kg/m2
10–36 % below RDA
for vitamins B1, B2,
B6, B12 and folate
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 125 ml enriched drink containing
30–50 % of the US RDA of
vitamins and minerals with
enhanced amounts of antioxi-
dants and 250 kcal (1046 kJ)
energy (once daily)
C: placebo (unspecified – twice
daily)
Duration: 6 months
General:
MMSE (screening)
Memory:
Fifteen-Word Learning Test (*P , 0·05)
Recognition Memory Test for Words (NS)
Executive function/working memory:
Category Fluency Test (Animals/
Professions) (*P , 0·05)
Vitamin B Aisen et al.
(2008)(76)
306
ITT: 409
50 þ Alzheimer’s dis-
ease,
older adult
USA MMSE 14–26
Mild to moderate
Alzheimer’s
disease
Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: B
T: 5 mg folate/d, 25 mg vitamin B6/d
and 1 mg vitamin B12/d
C: placebo (unspecified)
Duration: 18 months
General:
ADAS-cog (NS)
MMSE (NS) (screening and performance
measure)
Clinical Dementia Rating Sum of Boxes (NS)
Vitamin B Bryan et al.
(2002)(79)
211
ITT: 221
20–30
45–55
65–92
Adult female,
older adult
female
Australia n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T1: 750mg folate/d
T2: 15mg vitamin B12/d
T3: 75 mg vitamin B6/d
C: placebo (unspecified)
Duration: 5 weeks
Memory:
Activity Recall (NS)
Digit-Symbol-Coding Task, Symbol Recall
(WAIS) (NS)
Rey Auditory-Verbal Learning Test
(*P , 0·05)
Self-Ordered Pointing Task (NS)
Vocabulary (WAIS) (NS)
Executive function/working memory:
Digit Span Backwards (WAIS) (NS)
Letter–Number Sequencing (NS)
Stroop Colour–Word Test (NS)
Symbol Search (WAIS) (NS)
Spot The Word (NS)
Trail-Making Test (HRNTB) (NS)
Uses for Common Objects (NS)
Verbal Fluency (Initial Letter) († P , 0·05)
Verbal Fluency (Excluded Letter) (NS)
Psychomotor function/processing speed:
Boxes Test (NS)
Digit Symbol-Coding (WAIS) (NS)
Vitamin B Durga et al.
(2007)(77)
ITT: 818 50–70 Older adult The Nether-
lands
MMSE $ 24
Homocysteine
13–26mmol/l
Vitamin
B12 , 200 pmol/l
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: A
T: 800mg folic acid/d
C: placebo (unspecified)
Duration: 36 months
General:
MMSE (screening)
Global Cognitive Score (*P , 0·05)
Memory:
Thirty-Word Learning Test (*P , 0·05)
Executive function/working memory:
Concept Shifting Test (NS)
Stroop Colour–Word Test (NS)
Verbal Fluency Test (NS)
Psychomotor function/processing speed:
Letter Digit Substitution Test (*P , 0·05)
Stroop Colour–Word Test (word
reading) (NS)
Stroop Colour–Word Test (naming ink
colour) (NS)
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Table 1. Continued
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Vitamin B Eussen et al.
(2006)(71)
195 70 þ Older adult The Nether-
lands
MMSE . 19
Randomisation strati-
fied according to
sex, methylmalonic
acid concentration
at screening and
MMSE , and . 24
Mild B12 deficiency
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: A
T1: 1000 mg vitamin B12/d
T2: 1000 mg vitamin B12/d and
400 mg folic acid/d
C: placebo (unspecified)
Duration: 24 months
IQ:
Raven’s Progressive Matrices
General:
MMSE (NS) (screening and performance
measure)
Memory:
15-Word Learning Test (NS)
Digit Span Forward (WAIS) (NS)
Similarities Test (WAIS) (NS)
Word Recognition (NS)
Executive function/working memory:
Digit Span Backward (WAIS) (NS)
Rey–Osterreith Complex Figure Test (NS)
Stroop Colour–Word Test (NS)
Trail-Making Test (HRNTB) (NS)
Verbal Fluency (Initial Letter) (NS)
Verbal Fluency (Animals) (NS)
Psychomotor function/processing speed:
Finger-Tapping Task (NS)
Psychomotor Planning (NS)
Vitamin B Hvas et al.
(2004)(70)
140 Mean 74·5 Older adult Denmark 29 % MMSE , 25
36 % MMSE , 26 56 %
CAMCOG , 90
(mean 89)
27 % low scores in both
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: A
T: 1 mg vitamin B12/week
(BetolvexR)
C: placebo (1 ml isotonic sodium
chloride/week)
Duration: 3 months
General:
CAMCOG (NS)
MMSE (NS) (screening and performance
measure)
Memory:
12-Words Learning Test (NS)
Vitamin B Lewerin et al.
(2005)(78)
209 Mean 76·4 Older adult Sweden n/a Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: B
T: 0·5 mg vitamin B1/d, 0·8 mg folic
acid/d and 3 mg vitamin B6/d
C: placebo (unspecified)
Duration: 4 months
Memory:
Digit Span Forwards (WAIS) (NS)
Synonyms († P , 0·05)
Thurstone’s Picture Memory Test (NS)
Visual reproduction (WMS) (NS)
Executive function/working memory:
Block design (WAIS) (NS)
Digit Span Backwards (WAIS) (NS)
Figure classification (NS)
Psychomotor function/processing speed:
Digit Symbol (WAIS) (NS)
Identical forms († P , 0·05)
Postural-Locomotor-Manual Test (NS)
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Vitamin B McMahon et al.
(2006)(72)
253 65 þ Older adult New Zealand Plasma homocysteine
concentrations $
13mmol/l
Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: B
T: 1000mg folate/d, 500mg vitamin
B1/d and 10 mg vitamin B6/d
C: placebo (magnesium stearate þ
microcrystalline cellulose)
Duration: 24 months
IQ:
National Adult Reading Test
Raven’s Progressive Matrices
General:
MMSE (NS)
Memory:
Paragraph Recall Test († P , 0·05)
Rey Auditory-Verbal Learning Test (NS)
Executive function/working memory:
Category Word Fluency Test (NS)
Controlled Oral Word Association Test (NS)
Trail-Making Test (HRNTB) († P , 0·05)
Vitamin B Pathansali et al.
(2006)(73)
24 65 þ Older adult UK MMSE $ 27 Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 5 mg folic acid/d
C: placebo (unspecified)
Duration: 4 weeks
General:
MMSE (screening)
Memory:
Scanning Memory Sets (NS)
Executive function/working memory:
Continuous Attention Test (NS)
Psychomotor function/processing speed:
Four-Choice Reaction Time (NS)
Digit-Symbol Substitution (WAIS)
(† P , 0·05)
Vitamin B Seal et al.
(2002)(74)
26
(D/O: 5/31)
Mean 84·1 Older adult Australia MMSE: 6–28 (about
33 % had dementia)
Low vitamin B12
About 50 % cerebro-
vascular disease or
CVD
About 11 % type 2
diabetes
Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: B
T1: 10mg vitamin B12/d
T2: 50mg vitamin B12/d
C: placebo (daily 40 ml Australian
Pharmaceutical Formulary red
mixture þ2 ml hydrobenzoate
compound)
Duration: 1 month
General:
MMSE (NS) (screening and performance
measure)
Vitamin B van Uffelen et al.
(2008)(75)
ITT: 179
mITT: 152
(D/O: 13/152)
70–80 MCI, older adult The Nether-
lands
MMSE $ 24
TICS $ 19
Word Learning Test
Delayed
Recall # 5/10
Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: C
T: 5 mg folic acid/d, 0·4 mg vitamin
B12/d and 50 mg vitamin B6/d
C: placebo (unspecified)
Duration: 12 months
General:
MMSE (screening)
Telephone Interview for Cognitive Status
(screening)
Memory:
Auditory Verbal Learning Test (NS)
Executive function/working memory:
Stroop Colour–Word Test – Abridged (NS)
Verbal Fluency Test (NS)
Psychomotor function/processing speed:
Digit Symbol Substitution Test (WAIS)
(*P , 0·05)
Vitamin C/
vitamin E/
carotenoid
Smith et al.
(1999)(83)
205 60–80 Older adult UK MMSE $ 18
No vitamin sup-
plements in pre-
vious 3 months
Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: C
T: 12 mg b-carotene/d, 400 mg
vitamin E/d and 500 mg
vitamin C/d
C: placebo (unspecified)
Duration: 12 months
General:
MMSE (screening)
Memory:
20 Free Recall Task (NS)
Delayed Recognition Memory Task (NS)
Logical Reasoning Task (Baddeley) (NS)
Executive function/working memory:
Categoric Search Task (NS)
Focused Attention Task (NS)
Repeated-Digits Vigilance Task (NS)
Psychomotor function/processing speed:
Simple Reaction Time Task (NS)
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Table 1. Continued
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Mineral: Cu Kessler et al.
(2008)(82)
68
(D/O: 11)
50–80 Alzheimer’s dis-
ease, older
adult male,
postmeno-
pausal
female
Germany MMSE , 25
Clinical diagnosis of
probable Alzhei-
mer’s disease
(NINCDS-ADRDA
criteria)
5–10 mg Donepezil for
2 þ months
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 8 mg Cu/d
C: placebo (unspecified)
Duration: 12 months
General:
MMSE (NS) (screening and performance
measure)
ADAS-Cog (NS)
Mineral: Fe Murray-Kolb &
Beard
(2007)(81)
152
(D/O: 39)
18–35 Adult female USA Three sample groups:
1. Fe-sufficient
2. Non-anaemic
Fe-deficient
3. Anaemic
Fe-deficient
Design: single-blind randomised
placebo-controlled
Outcome: primary
Category: C
T: 60 mg Fe/d
C: placebo (unspecified)
Duration: 16 weeks
IQ:
Progressive Matrices (CAT)
Memory:
Learning Matrices (CAT)
Memory – Probe Recall (CAT)
Memory – Recognition Memory (CAT)
Executive function/working memory:
Attention – Stimulus Discrimination (CAT)
Attention – Tachistoscopic Threshold (CAT)
Memory – Sternberg Memory Search (CAT)
Psychomotor function/processing speed:
Attention – Reaction Time (CAT)
Factor analysed into:
1. Composite (Global) Score (***P, 0·005)
2. Performance (Accuracy) Score
(*P , 0·05)
3. Time (Reaction Time) Score (*P, 0·05)
4. Attention (*P , 0·05)
5. Memory (***P , 0·005)
6. Learning (*P , 0·05)
Mineral: Zn Maylor et al.
(2006)(80)
387 55–87 Adult, older
adult
UK MMSE $ 24 Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: A
T1: 30 mg Zn/d
T2: 15 mg Zn/d
C: placebo (unspecified)
Duration: 6 months
General:
MMSE (screening)
Memory:
PatternRecognitionMemory (CANTAB) (NS)
Spatial Span (CANTAB) (NS)
Executive function/working memory:
Matching to Sample Visual Search
(CANTAB) (*P, 0·05)
Spatial Working Memory (CANTAB)
(*P, 0·05)
Psychomotor function/processing speed:
Five-Choice Reaction Time (CANTAB) (NS)
Psychomotor Screening (CANTAB) (NS)
Simple Reaction Time (CANTAB) (NS)
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Flavonoid Basaria et al.
(2009)(25)
mITT: 84 46–76 Postmenopau-
sal female
USA n/a Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: B
T: 160 mg total isoflavones/d
C: placebo (20 g whole milk
protein/d þ same nutrients as
treatment, excluding isoflavones)
Duration: 12 weeks
IQ:
National Adult Reading Test (performance
measure) (NS)
Executive function/working memory:
Cube Comparisons Test (NS)
Trail-Making Test (HRNTB) (NS)
Verbal Fluency Test (NS)
Psychomotor function/processing speed:
Grooved Pegboard Test (NS)
Identical Pictures Test (NS)
Flavonoid Casini et al.
(2006)(84)
78 About 44–54 Postmenopau-
sal female
Italy n/a Design: randomised placebo-
controlled cross-over
Outcome: primary
Category: C
T: 60 mg total isoflavones/d
C: placebo (unspecified)
Duration: 13 months (2 £ 6 month
treatments with 1 month wash-out)
Memory:
Digit Span Forwards (WAIS) (NS)
Executive function/working memory:
Digit Span Backwards (WAIS) (*P , 0·05)
Digit Symbol Accuracy (WAIS) (*P , 0·05)
Visual Scanning Test (NS)
Psychomotor function/processing speed:
Digit Symbol Test (WAIS) (*P , 0·05)
Flavonoid Duffy et al.
(2003)(22)
36 50–65 Postmenopau-
sal female
UK n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 60 mg total isoflavones/d
C: placebo (colour-matched
lactose)
Duration: 12 weeks
IQ:
National Adult Reading Test (to check
baseline differences)
Memory:
Common Objects Recall Test (*P , 0·05)
Delayed Matching To Sample Test
(CANTAB) (NS)
Short Story Immediate Recall (NS)
Executive function/working memory:
Category Generation (NS)
IDED Rule Learning and Reversal
(CANTAB) (*P , 0·05)
Paced Auditory Serial Addition Test
(*P , 0·05)
Stockings of Cambridge (CANTAB)
(*P , 0·05)
Flavonoid Elsabagh et al.
(2005)(26)
Experiment 2
40 18–26 Young adult UK n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 120 mg Ginkgo biloba/d (Ginkyo,
Lichtwer Pharma – 25 % total
flavonoids, 6 % total terpenoids)
C: placebo (unspecified)
Duration: 6 weeks
Memory:
Delayed Recall of Words and Pictures
(CANTAB) (NS)
Pattern Recognition Memory (CANTAB) (NS)
Spatial Recognition Memory (CANTAB) (NS)
Executive function/working memory:
IDED Rule Learning and Reversal
(CANTAB) (NS)
Paced Auditory Serial Addition Test (NS)
Spatial Working Memory (CANTAB) (NS)
Stockings of Cambridge (CANTAB) (NS)
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Table 1. Continued
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Flavonoid File et al.
(2001)(21)
27 About 22–30 Young adult UK n/a Design: randomised controlled
Outcome: primary
Category: B
T: 100 mg total isoflavones/d (‘high’)
C: 0·5 mg total isoflavones/d (‘low’,
i.e. control)
Duration: 10 weeks
IQ:
National Adult Reading Test (to check
baseline differences)
Memory:
Common Objects Recall Test (*P , 0·05)
Delayed Matching To Sample Test
(CANTAB) (*P , 0·05)
Short Story Immediate Recall (*P , 0·05)
Executive function/working memory:
Category Generation Task (NS)
Digit Cancellation Test (NS)
IDED Rule Learning and Reversal
(CANTAB) (*P , 0·05)
Paced Auditory Serial Addition Test (NS)
Stockings of Cambridge (CANTAB)
(*P , 0·05)
Verbal Fluency (S) (NS)
Psychomotor function/processing speed:
Digit Symbol Test (WAIS) (NS)
Flavonoid File et al.
(2005)(19)
50 51–66 Postmenopau-
sal female
UK n/a Design: double-blind random-
ised placebo-controlled –
parallel groups
Outcome: primary
Category: C
T: 60 mg total isoflavones/d
C: placebo (unspecified)
Duration: 6 weeks
IQ:
National Adult Reading Test (to check
baseline differences)
Memory:
Common Objects Recall Test (*P , 0·05)
Delayed Matching To Sample Test
(CANTAB) (NS)
Short Story Immediate (*P , 0·05) and
Delayed Recall (NS)
Executive function/working memory:
Category Generation Task (NS)
IDED Rule Learning and Reversal
(CANTAB) (*P , 0·05)
Paced Auditory Serial Addition Test (NS)
Stockings of Cambridge (CANTAB)
(*P , 0·05)
Flavonoid Fournier et al.
(2007)(27)
79 48–65 Postmenopau-
sal female
USA n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T1: 70 mg total isoflavones/d
(supplement þ cows’ milk)
T2: 72 mg total isoflavones/d
(soya milk þ cows’ milk)
C: placebo (cows’ milk)
Duration: 16 weeks
Memory:
Corsi Block-Tapping Task (NS)
Digit Span Forwards (WAIS) (NS)
Pattern Recognition Task (NS)
Benton Visual Retention Test (NS)
Executive function/working memory:
Colour Matching Task (NS)
Digit Ordering Task († P , 0·05)
Stroop Colour–Word Task (NS)
Flavonoid Francis et al.
(2006)(87)
16 18–30 Adult female UK n/a Design: double-blind random-
ised placebo-controlled
cross-over
Outcome: primary
Category: B
T: 172 mg (‘high’) cocoa flavanols/d
C: 13 mg (‘low’) cocoa flavanols/d
Duration: 24 þ d (2 £ 5 d treat-
ments with at least 14 d
wash-out)
Executive function/working memory:
fMRI BOLD signal (*P , 0·05)
Letter–Digit Pairs Task (NS)
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Flavonoid Gleason et al.
(2009)(20)
30 62–89 Older adult
male, post-
menopausal
female
USA MMSE $ 27 Design: double-blind random-
ised placebo-controlled
Outcome: secondary
Category: C
T: 100 mg total isoflavones/d
C: placebo (maltodextrin þ caramel
food colour)
Duration: 6 months
General:
MMSE (screening)
Memory:
Boston Naming Test (NS)
Buschke Selective Reminding Test (NS)
Paragraph Recall Test (WMS) (NS)
Visual Spatial Learning Test (*P , 0·05)
Executive function/working memory:
Category Fluency Test (Animals)
(*P , 0·05)
Controlled Oral Word Association Test (NS)
Maze-Tracing Task (NS)
Rey–Osterrieth Complex Figure Test
(*P , 0·05)
Stroop Colour–Word Task († P , 0·05)
Trail-Making Test (HRNTB) († P , 0·05)
Psychomotor function/processing speed:
Grooved Pegboard (*P , 0·05)
Rey Complex Figure Test copy (*P , 0·05)
Flavonoid Ho et al.
(2007)(24)
191 55–76 Older adult
female
Hong Kong MMSE . 22
BMI 18–32 kg/m2
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: A
T: 80 mg total soya isoflavones/d
C: placebo (starch)
Duration: 6 months
General:
MMSE (NS) (screening and performance
measure)
Memory:
Boston Naming Test (NS)
Digit Span Forwards (NS)
Hong Kong List-Learning Test (NS)
Executive function/working memory:
Category Fluency (Animals/
Transportation) (NS)
Digit Span Backwards (WAIS) (NS)
Digit Vigilance Test (NS)
Rey–Osterrieth Complex Figure Test (NS)
Trail-Making Test (HRNTB) (NS)
Psychomotor function:
Finger-Tapping Test (NS)
Flavonoid Howes et al.
(2004)(85)
30 60 þ Postmenopau-
sal female
Australia MMSE . 26 Design: double-blind random-
ised placebo-controlled
cross-over
Outcome: primary
Category: B
T: 29 mg total isoflavones/d (red
clover extract ‘Rimostilw’)
C: placebo (unspecified)
Duration: 13 months (1 month run-in;
2 £ 6 month treatments with 1
month wash-out)
General:
MMSE (screening)
Memory:
Boston Naming Test (NS)
Digit Recall (WMS) (NS)
Memory 1 and 2 Tests (WMS) (NS)
Similarities Test (WAIS) (NS)
Verbal Memory 1 and 2 Tests (WMS) (NS)
Visual Memory 1 and 2 Tests (WAIS) (NS)
Executive function/working memory:
Arithmetic Test (WMS) (NS)
Block Design Test (WAIS) (NS)
Trail-Making Test (HRNTB) (NS)
Controlled Oral Word Association Test (NS)
Animals Test (NS)
Psychomotor function/processing speed:
Digit Symbol Test (WAIS) (NS)
Trail-Making Test – Part A (HRNTB) (NS)
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Table 1. Continued
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Flavonoid Kreijkamp-Kas-
pers et al.
(2004)(28)
202 60–75 Postmenopau-
sal female
The Nether-
lands
n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: A
T: 99 mg soya isoflavones/d in 36·5 g
powder/d þ vitamin B2, vitamin
B6, vitamin B12, folic acid, vitamin
D and Ca (amounts unspecified)
C: placebo (25·6 g total milk
protein/d) þ vitamin B2, vitamin
B6, vitamin B12, folic acid, vitamin
D and Ca (amounts unspecified)
Duration: 12 months
IQ:
Dutch Adult Reading Test (to check
baseline differences)
General:
MMSE (NS)
Memory:
Boston Naming Test (NS)
Digit Span Forwards (NS)
Doors Test (NS)
Rey Auditory-Verbal Learning Test (NS)
Executive function/working memory:
Digit Span Backwards (WAIS) (NS)
Trail-Making Test (HRNTB) (NS)
Verbal Fluency (NS)
Psychomotor Function/Processing Speed:
Digit Symbol Substitution Test (NS)
Flavonoid Kritz-Silverstein
et al.
(2003)(86)
56 55–74 Postmenopau-
sal female
USA n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 110 mg total soya isoflavones/d
C: placebo (unspecified)
Duration: 6 months
General:
MMSE (NS) (to check baseline differences)
Memory:
Logical Memory 1 and 2 Tests (NS)
Executive function/working memory:
Category Fluency (*P , 0·05)
Trail-Making Test (HRNTB) (NS)
Flavonoid Le Bars et al.
(2002)(23)
236 45–90 Alzheimer’s dis-
ease, older
adult
USA MMSE . 23
MMSE , 24
MMSE , 15
Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 120 mg G. biloba extract EGb
761/d (24 % total flavonoids, 6 %
total terpenoids)
C: placebo (unspecified)
Duration: 12 months
General:
MMSE (screening)
ADAS-Cog (*P , 0·05)
Flavonoid Mix & Crews
(2000)(88)
48 55–86 Older adult USA MMSE . 23 Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 180 mg G. biloba extract EGb
761/d (24 % total flavonoids,
6 % total terpenoids)
C: placebo (unspecified)
Duration: 6 weeks
General:
MMSE (screening)
Memory:
Logical Memory 1 and 2 Tests (WMS) (NS)
Visual Memory 1 and 2 Tests (WMS) (NS)
Executive function/working memory:
Stroop Colour–Word Task (NS)
Trail-Making Test (HRNTB) (NS)
Psychomotor function/processing speed:
Stroop Colour Naming Task (*P , 0·05)
Stroop Word Naming Task (NS)
Trail-Making Test – Part A (HRNTB) (NS)
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Flavonoid Ryan et al.
(2008)(90)
101 60–85 Older adult Australia n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T: 150 mg total flavonoids/d (French
maritime pine extract
‘Pycnogenolw’)
C: placebo (unspecified)
Duration: 3 months
Memory:
Word Recognition (CDR) (NS)
Executive function/working memory:
Digit Vigilance (CDR) (NS)
Numeric Working Memory (CDR) (NS)
Spatial Working Memory (CDR)
(*P , 0·05)
Psychomotor function:
Choice Reaction Time (CDR) (NS)
Simple Reaction Time (CDR) (NS)
Factor analysed as:
1. Power of Attention (NS):
Digit Vigilance (NS)
Simple Reaction Time (NS)
Choice Reaction Time (NS)
2. Quality of Working Memory (**P , 0·01):
Spatial Working Memory (*P , 0·05)
Numeric Working Memory (NS)
Flavonoid Santos et al.
(2003)(91)
48 60–70 Older adult
male
Brazil MMSE . 23 Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 80 mg G. biloba/d (Magister
Medicamentos – 24 % flavo-
noids, 6 % terpenoids)
C: placebo (unspecified)
Duration: 8 months
IQ:
Comprehension Test (WAIS)
(***P , 0·005)
Information Test (WAIS)
Information Test (WMS)
Vocabulary Test (WAIS) (**P , 0·01)
General:
MMSE (screening)
Orientation Test (WMS)
Memory:
Corsi Block-Tapping Test (***P , 0·005)
Digit Span Forward (WAIS)
Logical Memory Test (WMS)
Similarities Test (WAIS) (***P , 0·005)
Verbal Free Recall Test (NS)
Verbal Paired Associates Test (WMS)
(***P , 0·005)
Executive function/working memory:
Arithmetic Test (WAIS) (***P, 0·005)
Block Design Test (WAIS) (**P, 0·01)
Digit Span Backward (WAIS)
Mental Control Test (WMS) (***P , 0·005)
Object Assembly Test (WAIS)
(***P, 0·005)
Picture Arrangement Test (WAIS)
Picture Completion Test (WAIS)
Rey–Osterrieth Complex Figure Test
(**P, 0·01- delayed)
Concentrated Attention Test (TP)
(***P, 0·005)
Wisconsin Card Sorting Test (NS)
Psychomotor function/processing speed:
Digit Symbol Substitution Task (WAIS)
(***P, 0·005)
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Table 1. Continued
Nutrient Authors Subjects (n) Age (years)
Life stage
and/or sex Setting
Mental, nutrient
or health status
Design, outcome
status‡ and category§ Intervention, dose and duration Key findings
Flavonoid Stough et al.
(2001)(92)
50 18–40 Young adult Australia n/a Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: C
T: 120 mg G. biloba/d (Blackmore’s
Ginkgo Biloba Forte – 24 % total
flavonoids, 6 % total terpenoids)
C: placebo (unspecified)
Duration: 1 month
Memory:
Digit Span Forward (WAIS) (NS)
Rey Auditory-Verbal Learning Test
(**P , 0·01)
Executive function/working memory:
Digit Span Backward (WAIS) (*P , 0·05)
Trail-Making Test (HRNTB) (NS)
Working Memory (CBT) (NS)
Psychomotor function/processing speed:
Digit Symbol Substitution Task (WAIS)
(*P , 0·05)
Inspection Time Test (NS)
Simple Reaction Time (CBT) (NS)
SpeedofComprehensionTest (SCOLP)(NS)
Flavonoid van Dongen et al.
(2000)(29)
ITT: 214 50 þ Dementia, older
adult
The Nether-
lands
MMSE 7–29 Design: double-blind random-
ised placebo-controlled
Outcome: primary
Category: B
T1: 240 mg G. biloba extract EGb
761/d
T2: 160 mg G. biloba extract EGb
761/d
C: placebo (unspecified)
Duration: 24 weeks
General:
MMSE (screening)
Memory:
Digit Span Forward (WAIS) (NS)
8-Word List (NS)
Executive function/working memory:
Digit Span Backward (WAIS) (NS)
Psychomotor function/processing speed:
Trail-Making Test – Part A (NS)
Flavonoid Woo et al.
(2003)(89)
127 50–65 Postmenopau-
sal female
Hong Kong n/a Design: randomised controlled
Outcome: secondary
Category: C
T1: 100 mg total isoflavones/d (from
Pueraria lobata)
T2: HRT
C: no treatment
Duration: 3 months
General:
MMSE (*P , 0·05)
Memory:
Hong Kong List-Learning Test (NS)
Executive function/working memory:
Boston Naming Test (NS)
Trail-Making Test, also referred to as
Figure Trail 1 and 2 (*P , 0·05)
Psychomotor function:
Digit Symbol Test (cited in Results
section only) (*P , 0·05)
Finger-Tapping Test (NS)
MCI, mild cognitive impairment; DSM, Diagnostic and Statistical Manual of Mental Disorders; MMSE, Mini-Mental State Examination; T, treatment; C, control; ADAS-Cog, Cognitive element of the Alzheimer’s Disease
Assessment Scale; n/a, not applicable; IQ, intelligence quotient; ITT, intention-to-treat; D/O, dropped out; RDA, recommended daily allowance; WAIS, Wechsler Adult Intelligence Scale (all versions); HRNTB,
Halstead–Reitan Neuropsychological Test Battery; CAMCOG, Cambridge Cognitive Examination; WMS, Wechsler Memory Scale (all versions); mITT, modified intention-to-treat; TICS, Telephone Interview for
Cognitive Status; NINDS-ADRDA, National Institute of Neurological Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association; CAT, Cognitive Abilities Test; CANTAB, Cambridge
Neuropsychological Test Automated Battery; IDED, Intra Dimensional/Extra Dimensional Set Shifting Task; fMRI, functional magnetic resonance imaging; BOLD, blood oxygenation level-dependent; CDR, cognitive
drug research; TP, Toulouse–Pieron Test; CBT, Cognometer Battery of Tests; SCOLP, Speed and Capacity of Language-Processing Test; HRT, hormone replacement therapy.
* Mean treatment group scores were significantly better than those of the control group: *P , 0·05, **P , 0·01, ***P , 0·005.
† Mean treatment group scores were significantly worse than those of the control group: † P , 0·05, †† P , 0·01, ††† P , 0·005.
‡ Study designed with cognitive function as ‘primary’ or ‘secondary’ target outcome measure.
§ Study graded for quality: category A, highest quality, no bias; category B, medium quality, some bias but results are deemed valid; category C, poor quality, significant bias that may invalidate the results.
k 1 IU vitamin A ¼ 0·3mg retinol or 0·6mg b-carotene.
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with multiple populations and settings; none was specifi-
cally designed with reference to micronutrient or phyto-
chemical interventions. Revealingly, in the remaining
eighteen studies(20,24 – 26,66,67,69,70,72,74,75,78,82,84,86,89,91,92),
no rationale for task choice was given, although four of
these included dementia patients, so task selection was
naturally restricted to measures appropriate to these
populations(66,70,74,82).
Range of cognitive measures used
Across the thirty-nine RCT under investigation, 121
cognitive tasks were identified (see Table 2). After an
analysis of the primary neuropsychological focus for each
measure, it was calculated that thirty-seven memory tasks
(for example, episodic, semantic and short-term), twenty-six
executive function tasks, fourteen working memory tasks,
nineteen psychomotor processing speed tasks, nine general
or ‘global’ tasks, thirteen intelligence quotient (IQ) tasks
(mostly to measure baseline between-group differences),
two motor function tasks and one perception measure had
been employed (see Table 2).
Generally, there was little correspondence in measures
between studies, with occasional notable exceptions. For
instance, researchers from King’s College London(19,21,22)
used the same seven executive function and memory tasks in
their flavonoid intervention studies on older populations as
had previously been used in a group of 22-to 30-year-old
subjects(19). Two tasks which were non-significant in the
earlier study were excluded. While they found the Common
Objects Recall Test and the Cambridge Neuropsychological
Test Automated Battery (CANTAB) Intra Dimensional/
Extra Dimensional Set Shifting Task Rule Learning and
Reversal tests to be sensitive to flavonoid treatment in all
three studies, these tasks appear to have been rarely
employed elsewhere (see Table 2).
Executive function
Among the executive function tasks, one measure was
primarily categorised as ‘focused attention’ and five as
‘sustained attention’. Four measured ‘switching’ or ‘shift-
ing’, and one measured ‘inhibition’. None focused
specifically on ‘updating’, although two tasks described
here as measuring the more generalised ‘frontal function’
may include varying degrees of ‘updating’ as well as
‘switching’ and ‘inhibition’. In addition, there were five
measures of ‘verbal fluency’, four ‘visual search’, two
‘decision-making’ and one ‘planning’ task (see Table 2).
Verbal fluency tasks were used in sixteen studies, and
some positive effects were shown in four: flavonoids, B
vitamins and multivitamins and minerals(20,68,79,86).
Verbal fluency tasks included category generation, where
participants are asked to name as many category members
as possible (for example, animals, transportation, etc), and
initial-letter verbal fluency, where participants generate
words beginning with a particular letter in a given time
(for example, F, A or S). Category fluency tasks, which are
also thought to involve an element of semantic memory(62),
were significant in the two flavonoid studies(20,86)
and the multivitamin and minerals study(68), although
Wouters-Wesseling et al. (68) reported significant baseline
differences on this task, suggesting potential randomisation
issues in this study. The less semantically demanding
initial-letter fluency tasks were generally non-significant,
with the exception of Bryan et al. (79) who found
significantly better fluency scores for vitamin B6 and
placebo than for folate or vitamin B12.
The Stroop Colour – Word Task, which measures
inhibition, was used in seven studies, and showed positive
effects of flavonoid treatment in two(20,88). Conspicuously,
the Trail-Making Task, which featured in thirteen
studies(20,24,25,28,29,71,72,79,85,86,88,89,92) showed only a nega-
tive effect of treatment for vitamin B(72) and flavonoids(20).
Although a common measure of ‘switching’, it is possible
that the pen and paper nature of the Trail-Making Task
limits its sensitivity. However, none of the four ‘switching’
tasks reviewed here has shown a positive treatment effect,
perhaps suggestive of a more general limiting condition.
The Intra Dimensional/Extra Dimensional Set Shifting
Task Rule Learning and Reversal task which measures
frontal function, involving aspects of ‘switching’ or
‘shifting’, ‘updating’ and ‘inhibition’, and the Stockings
of Cambridge planning task showed some sensitivity to
flavonoid treatment for both young(19) and older(21,22)
adults, for doses of 60–100 mg total isoflavones per d, over
periods ranging from 6 to 12 weeks (see Tables 1 and 2).
However, both tests failed to show any effect in a 6-week
G. biloba trial in young adults(26).
Working memory
Eight measures of visuospatial or spatial working memory
were identified, along with three numerical measures, one
verbal measure, and one test of working memory span (for
example, the Digit Span Backwards task which measures
working memory capacity), which was used in nine studies
(see Table 2). The eight visuospatial measures, used in
eleven different studies, showed significant effects in four
studies, with respect to flavonoid treatments(20,90,91) and
Zn(80), although Santos et al. (91) (n 48) and Gleason et al. (20)
(n 30) had relatively small sample sizes, and the
randomisation process adopted by Santos et al. (91) may
not have been reliable as they reported baseline differences
in IQ between groups.
Two computerised tasks described as measuring ‘spatial
working memory’ appeared sensitive to Zn(80) and
flavonoid(90) treatment. Encouragingly, while they were
described as measuring the same cognitive function, the
tasks themselves varied considerably, suggesting that the
observed effects were specific to domain rather than task.
For instance, the Zn study Cambridge Neuropsychological
Test Automated Battery (CANTAB) task required partici-
pants to search for, and remember, the locations of blue
tokens inside a set of red boxes. In the Ryan et al. (90) study,
participants were shown a picture of a house and were asked
to memorise the locations of nine lit windows; subsequently,
they were shown individually lit windows and asked to
decide if they had been lit earlier. The Rey–Osterrieth
Complex Figure Test, used in four studies, showed
significant positive treatment effects in two(20,91).
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Table 2. Neuropsychological focus for 121 measures used in thirty-nine human chronic dietary intervention randomised controlled trial (RCT) studies
Executive function Memory Motor IQ
Primary
neuropsychological
focus Task and RCT reference
Significant positive or
negative treatment effects
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General/global Alzheimer’s Disease Assessment
Scale
Cognitive Subscale(23,66,76,82)
Positive: flavonoid(23) Y Y Y Y Y Y Y Y
General/global Berliner Amnesie Test(69) – Y Y Y
General/global Cambridge Cognitive
Examination(70)
– Y Y Y Y Y Y Y Y Y
General/global Clinical Dementia Rating Scale Sum
of Boxes(76)
– Y Y Y Y
General/global Mini-Mental State Examination:
Screening(23,24,68,77,88)
Outcome
measure(24,28,65,66,68,70–74,76,82,86,89)
Positive: flavonoid(89) Y Y Y Y Y Y Y Y
General/global Orientation Test (WMS)(91) – Y Y Y
General/global Picture Arrangement Test (WAIS)(91) – Y Y
General/global Syndrom Kurtz Task(65) – Y Y Y Y Y
General/global Telephone Interview for Cognitive
Status (screening)(66)
– Y Y Y Y Y Y Y Y
IQ: crystallised intelligence Comprehension Test (WAIS)(91) Positive: flavonoid(91) Y
IQ: crystallised intelligence Dutch Adult Reading Test: baseline
measure(28)
– Y
IQ: crystallised intelligence Information Test (WAIS)(91) – Y
IQ: crystallised intelligence Information Test (WMS)(91) – Y
IQ: crystallised intelligence National Adult Reading Test:
Baseline measure(19,21,22,65,72)
Outcome measure(25)
– Y
IQ: crystallised intelligence Vocabulary (WAIS)(79,91) Positive: flavonoid(91) Y
IQ: fluid intelligence Alice Heim’s 4 and 5 Tests of
General Intelligence: baseline
measure:(65)
– Y
IQ: fluid intelligence Figure Classification(78) – Y
IQ: fluid intelligence KurzTest fu¨r Allgemeine Intelligenz:
baseline measure(69)
– Y
IQ: fluid intelligence Learning Matrices (CAT)(81) – Y
IQ: fluid intelligence Logical Reasoning Task(83) – Y
IQ: fluid intelligence Progressive Matrices (CAT)(81) – Y
IQ: fluid intelligence Raven’s Progressive Matrices:
baseline measure(71,72)
–
Exec Fn: decision-making Categoric Search Task(83) – Y Y Y
Exec Fn: decision-making Attention – Tachistoscopic
Threshold (CAT)(81)
– Y Y
Exec Fn: focused attention Focused Attention Task(83) – Y Y Y
Exec Fn: frontal function IDED Rule Learning and Reversal
(CANTAB)(19,21,22,26)
Positive: flavonoid(21,22) Y Y Y Y Y
Exec Fn: frontal function Self-Ordered Pointing Task(79) – Y Y Y Y
Exec Fn: frontal function Wisconsin Card Sorting Test(91) – Y Y Y Y
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Exec Fn: inhibition Stroop Colour–Word
Task(20,27,71,75,77,79,88)
Positive: flavonoid(88)
Negative: flavonoid(20)
Y Y Y
Exec Fn: planning Stockings of Cambridge
(CANTAB)(19,21,22,26)
Positive: flavonoid(19,21,22) Y Y
Exec Fn: sustained
attention
Continuous Attention Test(73) – Y Y Y
Exec Fn: sustained
attention
Digit Vigilance Test/Digit
Vigilance Test (CDR)(24,90)
– Y Y Y
Exec Fn: sustained
attention
Mental Control Task(91) Positive: flavonoid(91) Y Y Y
Exec Fn: sustained
attention
Paced Auditory Serial Addition
Test(19,21,22,26)
Positive: flavonoid(22) Y Y Y
Exec Fn: sustained
attention
Repeated-Digits Vigilance Task(83) – Y Y Y
Exec Fn: switching/shifting Concept Shifting Test(77) – Y Y Y
Exec Fn: switching/shifting Letter–Digit Pairs Task(87) – Y Y Y
Exec Fn: switching/shifting Maze-Tracing Task(20) – Y Y Y
Exec Fn: switching/shifting Trail-Making Test
(HRNTB)(20,24,25,28,29,71,72,79,85,86,88,89,92)
Negative: B vitamins(72)
Negative: flavonoid(20)
Y Y Y Y
Exec Fn: verbal fluency Category Fluency Tests:
Category Fluency Test (Animals,
Transportation), Category Word
Fluency Test (Animals,
Professions)(20,24,68,71,72,85,86)
Positive: flavonoid(20,86)
Positive: multivitamins/
multiminerals(68)
Y Y Y
Exec Fn: verbal fluency Category Generation Task(19,21,22) – Y Y Y
Exec Fn: verbal fluency Controlled Oral Word Association
Test (20,72,85)
– Y Y
Exec Fn: verbal fluency Uses for Common Objects(79) – Y Y Y
Exec Fn: verbal fluency Verbal Fluency Tests: Verbal
Fluency Test (Initial Letter,
Excluded Letter)(21,25,28,67,71,75,77,79)
Negative: B vitamins(79) Y Y
Exec Fn: visual search Digit Cancellation Test(21) – Y Y Y
Exec Fn: visual search Matching to Sample Visual Search
(CANTAB)(80)
Positive: Zn(80) Y Y Y
Exec Fn: visual search Sternberg Memory Search Task
(CAT)(81)
– Y Y Y
Exec Fn: visual search Visual Scanning Test(84) – Y Y Y
Working memory Working Memory (CBT)(92) – Y
Working memory:
numerical
Arithmetic Test (WAIS/WMS)(85,91) – Y Y
Working memory:
numerical
Numeric Working Memory (CDR)(90) – Y Y
Working memory:
numerical
Scanning Memory Sets(73) – Y Y
Working memory: span Digit Span Backward
(WAIS)(24,28,29,71,78,84,91,92)
Positive: flavonoid(84,92) Y
Working memory: verbal Digit Ordering(27) Negative: flavonoid(27) Y Y
Working memory: visual/
visuospatial
Block Design Test (WAIS)(78,85,91) Positive: flavonoid(91) Y Y
Working memory: visual/
visuospatial
Colour Matching Task(27) – Y Y
Working memory: visual/
visuospatial
Cube Comparisons Test(25) – Y Y
Working memory: visual/
visuospatial
Object Assembly Test (WAIS)(91) Positive: flavonoid(91) Y Y Y
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Table 2. Continued
Executive function Memory Motor IQ
Primary
neuropsychological
focus Task and RCT reference
Significant positive or
negative treatment effects
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Working memory: visual/
visuospatial
Picture Completion Test (WAIS)(91) – Y Y
Working memory: visual/
visuospatial
Rey–Osterrieth Complex Figure
Test(20,24,71,91)
Positive: flavonoid(20,91) Y Y Y Y Y
Working memory: visual/
visuospatial
Spatial Working Memory Task
(CANTAB)(26,80)
Positive: Zn(80) Y Y
Working memory: visual/
visuospatial
Spatial Working Memory Task
(CDR)(90)
Positive: flavonoid(90) Y Y
Memory: episodic – verbal Activity Recall(79) – Y
Memory: episodic – verbal Buschke Selective Reminding
Test(20)
– Y Y Y
Memory: episodic – verbal Common Objects Recall
Test(19,21,22)
Positive: flavonoid(19,21,22) Y Y Y Y
Memory: episodic – verbal Delayed Recall of Words and
Pictures (CANTAB)(26)
– Y Y Y Y
Memory: episodic – verbal Delayed Recognition Memory
Task(83)
– Y Y Y Y
Memory: episodic – verbal Hong Kong List-Learning Test(24,89) – Y Y Y
Memory: episodic – verbal Logical Memory Test I & II
(WMS)(86,88,91)
– Y Y Y
Memory: episodic – verbal Memory 1 and 2 Tests (WMS)(85) – Y Y Y
Memory: episodic – verbal Memory – Probe Recall (CAT)(81) – Y Y
Memory: episodic – verbal Memory – Recognition Memory Test
(CAT)(81)
– Y Y Y Y
Memory: episodic – verbal Paragraph Recall Test (WMS)(20,72) Negative: B vitamins(72) Y Y Y
Memory: episodic – verbal Recognition Memory Test For
Words(68)
– Y Y Y Y
Memory: episodic – verbal Rey Auditory-Verbal Learning
Test(28,72,75,79,92)
Positive: B vitamins(79)
Positive: flavonoid(92)
Y Y Y
Memory: episodic – verbal Short Story Recall (WMS)(19,21,22) Positive: flavonoid(19,21) Y Y Y
Memory: episodic – verbal Verbal Memory 1 and 2 Tests
(WMS)(85)
– Y Y Y
Memory: episodic – verbal Verbal Paired Associates Test
(WMS)(91)
Positive: flavonoid(91) Y Y Y Y
Memory: episodic – verbal Word Learning Tests (Immediate
and Delayed Recall/Recogni-
tion): 10-Word Verbal Memory
Test/12-Word Learning Test/
15-Word Learning Test/
20-Word Free Recall Task/
30-Word Recall Test/Word
Learning Test/Word Recognition
Test (CDR)(29,68,70,71,77,83,90,91)
Positive: B vitamins(77)
Positive: multivitamins/
multiminerals(68)
Y Y Y Y
Memory: episodic – verbal Word Scan Task(65) – Y Y Y Y
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Memory: episodic –
visual/visuospatial
Attention – Stimulus Discrimination
(CAT)(81)
– Y Y Y
Memory: episodic –
visual/visuospatial
Benton Visual Retention Test(27) – Y Y Y
Memory: episodic –
visual/visuospatial
Corsi Block-Tapping (WAIS)(27,91) Positive: flavonoid(91) Y Y Y
Memory: episodic –
visual/visuospatial
Delayed Matching To Sample Test
(CANTAB)(19,21,22)
Positive: flavonoid(21) Y Y Y Y
Memory: episodic –
visual/visuospatial
Doors Test(28) – Y Y Y
Memory: episodic –
visual/visuospatial
Pattern Recognition/Pattern
Recognition Memory
(CANTAB)(26,27,80)
– Y Y Y Y
Memory: episodic –
visual/visuospatial
Spatial Recognition Memory
(CANTAB)(26)
– Y Y Y Y
Memory: episodic –
visual/visuospatial
Thurstone’s Picture Memory Test(78) – Y Y Y
Memory: episodic –
visual/visuospatial
Visual Memory 1 and 2 Tests
(WAIS)(85,88)
– Y Y Y
Memory: episodic –
visual/visuospatial
Visual Reproduction Test(78) – Y Y Y
Memory: semantic Boston Naming Test(20,24,28,85,89) – Y
Memory: semantic Similarities Test(71,85,91) Positive: flavonoid(91) Y
Memory: semantic Spot The Word Vocabulary Test
(SCOLP)(79)
– Y Y
Memory: semantic Synonyms Task(78) Positive: B vitamins(78) Y
Memory: short term Digit Recall (WMS)(85) – Y Y Y
Memory: short term Digit Span Forward
(WAIS)(24,27–29,67,71,78,84,91,92)
– Y Y Y
Memory: short term Visual Spatial Learning Test(20) Positive: flavonoid(20) Y Y Y
Memory: short term Spatial Span/Spatial Span
(CANTAB)(80)
– Y Y
Memory: short term Sternberg Memory Scanning
Task(65)
– Y Y
Psychomotor: processing
speed
Attention – Reaction Time (CAT)(81) Positive: Fe(81) Y Y
Psychomotor: processing
speed
Boxes Test(79) – Y Y
Psychomotor: processing
speed
Choice Reaction Time tasks: Choice
Reaction Time/Choice Reaction
Time (CDR)/Four-Choice Reac-
tion Time/Five-Choice Reaction
Time (CANTAB)(65,73,80,90)
Positive: multivitamins(65) Y Y Y
Psychomotor: processing
speed
Digit Symbol-Coding/Digit Symbol
Substitution Task/Digit Symbol
Accuracy
(WAIS)(21,28,73,75,78,79,84,
85,89,91,92)
Positive: B vitamins(75)
Negative: B vitamins(73)
Positive: flavonoid(84,91,92)
Y Y Y
Psychomotor: processing
speed
Finger-Tapping Task(24,71,89) – Y Y
Psychomotor: processing
speed
Grooved Pegboard(20,25) Positive flavonoid(20) Y Y
Psychomotor: processing
speed
Identical Forms Task(78) Positive: B vitamins(78) Y Y Y
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Table 2. Continued
Executive function Memory Motor IQ
Primary
neuropsychological
focus Task and RCT reference
Significant positive or
negative treatment effects
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Psychomotor: processing
speed
Identical Pictures Test(25) – Y Y Y
Psychomotor: processing
speed
Inspection Time Task(92) – Y Y Y
Psychomotor: processing
speed
Letter Digit Substitution Test(77) Positive: B vitamins(77) Y Y Y
Psychomotor: processing
speed
Psychomotor Screening
(CANTAB)(80)
– Y Y
Psychomotor: processing
speed
Simple Reaction Time Task/Simple
Reaction Time (CAN-
TAB/CDR/CBT)(80,83,90,92)
– Y Y
Psychomotor: processing
speed
Speed of Comprehension Test
(SCOLP)(92)
– Y Y Y
Psychomotor: processing
speed
Stroop Colour Naming Task(88) Positive: flavonoid(88) Y Y
Psychomotor: processing
speed
Stroop Word Naming Task(88) – Y Y
Psychomotor: processing
speed
Symbol Search Test (WAIS)(69,79) – Y Y Y
Psychomotor: processing
speed
Concentrated Attention Test (TP)(91) Positive: flavonoid(91) Y Y
Psychomotor: processing
speed
Rey Complex Figure Test copy(20) Positive: flavonoid(20) Y Y Y
Psychomotor: processing
speed
Trail-Making Test – Part A
(HRNTB)(85,88)
– Y Y Y
Motor function Postural-Locomotor-Manual Test(78) – Y
Motor function Psychomotor Planning(71) – Y
Perception Critical Flicker Fusion(65) – Y
Grand total 1 5 4 7 3 3 2 5 5 47 36 13 0 0 0 10 36 10 29 27 10 37 21 3 5 8
IQ, intelligence quotient; Y, yes; WMS, Wechsler Memory Scale; WAIS, Wechsler Adult Intelligence Scale; CAT, Cognitive Abilities Test; Exec Fn, Executive function; IDED, Intra Dimensional/Extra Dimensional Set
Shifting Task; CANTAB, Cambridge Neuropsychological Test Automated Battery; CDR, cognitive drug research; HRNTB, Halstead–Reitan Neuropsychological Test Battery; CBT, Cognometer Battery of Tests;
SCOLP, Speed and Capacity of Language-Processing Test; TP, Toulouse–Pieron Test.
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The working memory span task (the Digit Span
Backward test) showed significant effects in only two of
eight studies, for flavonoids(84,92), although as mentioned
earlier, it is difficult to judge the quality of these results due
to the lack of statistical rigour to which the data were
subjected, and/or to lack of information provided.
Memory
In terms of the other memory processes under investigation,
thirty-one studies investigated episodic memory, or memory
for events. Episodic memory tests included both verbal
and visual tasks, such as word learning, paragraph recall,
picture recall, recall of common objects and delayed
matching to sample. Tasks showed significant treatment
effects in a quarter of the studies: five flavonoid
RCT(19,21,22,91,92), two B vitamin RCT(77,79) and one
multivitamin and mineral RCT(68). A negative effect of
treatment was found for B vitamins(72).
As can be seen from Table 2, verbal episodic memory
tasks such as the Rey Auditory Verbal Learning Test and
other word learning tests showed some sensitivity to B
vitamin, multivitamin and mineral, and flavonoid treat-
ments, whereas visual or visuospatial episodic tasks were
more sensitive to flavonoid treatment.
Only six of the episodic memory tests are described as
such in five of the RCT under review(19,21,22,26,28) (see
Table 2). Nineteen other episodic memory tasks were
defined instead as testing verbal memory. Twelve further
tasks were defined as visual, spatial, or visuospatial memory
tasks. In total, therefore, thirty-seven of the reviewed tasks
could be described as measuring episodic memory. This
includes any verbal or visuospatial memory tasks without a
major working memory element, but excludes memory span
measures, which are judged to measure short-term memory.
There was a wide range of tasks designed to measure
verbal episodic memory, including immediate and delayed
recall and/or recognition of between ten and thirty words
(see ‘Word-Learning Tests’ in Table 2), immediate and
delayed paragraph recall, and paired-associates cued-recall,
all of which may impose different levels of cognitive
demand, and access different types of cognitive processes
and domains. Visuospatial episodic measures encompassed
an equally wide range of tasks, ranging from picture
recall and reproduction, for example, the Benton Visual
Retention Test, to memory for faces, for example, the
Wechsler Memory Scale(96) Faces I and Faces II subscale.
Immediate and delayed recall or recognition for the
same task are counted here as a single memory task, for
example, the Wechsler Memory Scale Logical Memory
Test I and II, Memory 1 and 2 Tests, Verbal Memory 1 and
2 Tests and the Wechsler Adult Intelligence Scale(97)
Visual Memory 1 and 2 Tests.
Eight studies measured semantic
memory(20,24,28,71,78,79,85,89), but only one vitamin B RCT
showed any positive effect of treatment(78). Again, there was
a wide variation between the tasks: the Spot The Word
Vocabulary Test requires participants to differentiate
between words and non-words(79), whereas the Wechsler
Adult Intelligence Scale Similarities Test(71,85,91) requires
participants to describe similarities between sets of nouns.
The Boston Naming Test measures the ability to name
picture objects(20,24,28,85,89), and the Synonyms task
measures the ability to select correct synonyms for given
words(78).
Short-term memory, as measured by the digit span or
recall tasks and the Sternberg Memory Scanning Task, was
measured in thirteen studies. While a decline was found in a
flavonoid study(85), this effect disappeared after the authors
corrected for type I error. No other effects of treatment were
found for short-term memory measures.
As can be seen from Table 2, cognitive domains which
have yet to be explored in micronutrient human RCT
include procedural, implicit and prospective memory; it is
therefore not possible to provide a more comprehensive
assessment of the relationship between these dietary
components and the full range of memory processes at
this stage.
Psychomotor/motor function
Psychomotor processing speed was measured in twenty-
three studies, using a total of nineteen psychomotor tasks.
The most popular type of test, used in eleven studies, was
the Wechsler Adult Intelligence Scale Digit Symbol
Substitution or Digit Symbol Coding Test, designed as a
measure of psychomotor processing speed(62) but often used
as a measure of working memory. These tasks were shown
to be sensitive to flavonoid(84,88,91,92) and vitamin B(73,75)
treatments. Three other psychomotor processing speed tasks
were also sensitive to vitamin B treatment: the Boxes
Test(79), Identical Forms Task(78) and Letter Digit
Substitution Test(77). The next most popular paradigm was
choice reaction time (CRT), a complex form of the simple
reaction time (SRT) paradigm used in four RCT. The CRT
task also has a decision-making component and was
sensitive to a multivitamin intervention(65), unlike the SRT
which was non-significant across four studies(80,83,90,92).
Multiple cognitive measures
Within a domain, the number of measures used varied
widely from study to study. Whereas the majority selected
one or two measures to represent a single cognitive domain,
Santos et al. (91) used twenty-two measures overall,
including ten executive function tasks, six memory tests
and four IQ performance measures. Bryan et al. (79) used
eight measures of executive function and working memory,
and five other memory tasks. Gleason et al. (20) used six
executive function tasks and four memory measures and
Howes et al. (85) used four executive function tasks and six
memory measures.
One advantage of the multiple measures approach is that
it provides an opportunity for researchers to compute a
composite measure of a particular domain, thus controlling
in part for the idiosyncrasies of individual tasks and the
potential for type I error. Murray-Kolb & Beard(81) and
Ryan et al. (90) used factor analysis to group ‘families’ of
tasks to reduce the number of cognitive variables. Neither of
these studies found significant results using these composite
scores. Notwithstanding this, the approach has some
promise, although caution is needed when deriving
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composite measures, as cognitive tasks are likely to be
correlated and therefore some statistical techniques may not
be warranted.
With an increasing number of cognitive tasks there comes
an increased danger of type I error during analysis. This
issue was dealt with in two cases(22,27) by using multiple
ANOVA, which reduces overall error.
Global cognitive measures
Five studies targeted general rather than specific cognition,
using only general or ‘global’ measures of cognitive
functions such as the MMSE, the ADAS-Cog and
Hasegawa’s Dementia Rating Scale(23,66,74,76,82). Two
RCT relied solely on the MMSE or the ADAS-Cog for
measurement of cognitive function: one of these studied the
effects of flavonoids on Alzheimer’s disease patients,
showing a significant positive effect of flavonoid treatment
over 12 months(23). The other found no effect of vitamin B
treatment in older adults with a MMSE score ranging from 6
to 28 out of a possible 30(74). Overall, the MMSE was
used as a performance measure in fourteen
RCT(24,28,65,66,68,70 – 74,76,82,86,89) but only showed a signifi-
cant effect of treatment in one(89), although this may have
been due to the inclusion of cognitively impaired controls
with a baseline MMSE score of less than 24 out of 30. The
ADAS-Cog was used in four studies(23,66,76,82), and showed
significant effects of treatment for patients with a baseline
MMSE score of less than 24 in one 12-month flavonoid
Alzheimer’s disease intervention(23), with the placebo group
showing a significantly greater decline on the ADAS-Cog
than the treatment group.
Cognitive screening and baseline population measures
Twelve studies (31 %) included participants with
MMSE scores of less than 24 out of 30, which
is suggestive of cognitive impairment or demen-
tia(23,24,29,66,68,70,71,74,76,82,83,91). Eighteen studies (46 %)
did not screen for cognitive impairment; of these,
thirteen included participants over the age of
50 years(19,22,25,27,28,65,69,78,79,84,86,89,90) and may also,
therefore, have unwittingly included cognitively impaired
participants. Three studies reported baseline statistical
differences in cognitive performance(68,69,91). Eleven studies
did not report statistical baseline comparisons for any
cognitive performance measures, making it difficult to
assess the efficacy of their randomisation pro-
cess(19,20,26,27,81 – 84,88,89,92), and Bryan et al. (79) only
provided this information for some of their cognitive
tasks. Casini et al. (84) collected cognitive data at the end of
each treatment arm in their cross-over design, thereby
providing no real baseline cognitive data.
In general, IQ tests were used to provide measures of
possible baseline differences between treatment groups,
although Santos et al. (91) used four crystallised intelligence
IQ tasks as performance measures and, unusually, found
significant differences after 8 months of treatment with
G. biloba. Examination of means shows that the treat-
ment group had generally lower baseline IQ scores but
similar endpoint scores on these measures, suggesting a
measurement correction rather than a treatment effect.
Reasons given for null results
Fourteen RCT were considered by their authors to be
underpowered with too-small sample sizes. Sixteen
suggested that the duration of the treatment was too
short, in interventions that ranged from 4 weeks(73,74) to
2 years(72). Two suggested that the doses used were
inadequate(24,72). Authors of six RCT warned that the
results may not be generalisable across other popu-
lations(25,72,76,77,80,92); for instance, as the authors pointed
out, vitamin B trials may have different results when carried
out in countries where fortification with folic acid is
mandatory(76,77). With a few exceptions(65,87,88), researchers
have not focused on the sensitivity of the cognitive measures
when explaining null results.
Discussion
Less than half the studies reviewed showed any positive
treatment effects of target nutrients. In terms of looking at
efficacy for individual cognitive tasks, this equates to only
thirty-eight out of 121 (31 %) displaying some sensitivity
to chronic supplementation. This is consistent with
findings from other reviews of nutrition and prevention of
cognitive decline, such as Hoyland et al. (98), Jia et al. (17)
and Macready et al. (18). Hoyland et al. (98), for instance,
found that in macronutrient intervention studies, the most
significant performance differences occurred with the most
demanding tasks and with delayed memory performance.
It is possible that the tasks showing the greatest sensitivity in
micronutrient and flavonoid interventions may also impose
the greatest cognitive demands and/or memory performance
stimulus–response delays; this is certainly worth consider-
ing for systematic investigation in the future, but it has not
yet been explored in the field of micronutrient or flavonoid
human chronic RCT research.
The quality-grading exercise revealed only six studies
that could be considered as examples of best practice: three
vitamin B studies(70,71,77), two flavonoid studies(24,28) and a
Zn RCT(80). The remainder failed to meet one or more of
the criteria set out in the Methods section for category A,
including: inappropriate comparator, outcome measure,
statistical method and/or reporting; insufficient power;
reporting errors; and unclear description of the population,
setting or reporting of drop-outs. Ideally, there should be
less than 20 % drop-out and RCT should be double-blinded
where possible. While findings were mixed, and interpret-
ation of the findings is made more challenging by
methodological shortcomings in individual studies, some
cognitive domains did show more sensitivity to nutritional
supplementation than others. Specifically, there were reports
of positive treatment effects on tasks with a spatial memory
component with Zn and flavonoids in two RCT, one of
which was graded category A(80). Vitamin B and Fe showed
benefits for psychomotor processing speed, with the vitamin
B study also classified as a category A RCT(77), although
this was not supported by findings from the two other
category A vitamin B studies(70,71). Flavonoids also showed
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positive effects for executive function, in particular frontal
function (Intra Dimensional/Extra Dimensional Set Shifting
Task Rule Learning and Reversal Task), inhibition (Stroop
Colour–Word Task), planning (Stockings of Cambridge
Task), sustained attention (Paced Auditory Serial Addition
Test), and category fluency tasks, although some of these
findings are from category C studies and should therefore be
interpreted with a degree of caution. In addition, Zn
generated an improvement on a visual search task (Match to
Sample)(80). Finally, there were also some nutrient effects on
various episodic memory tasks, in particular the Common
Objects Recall Test, the Rey Auditory-Verbal Learning Test,
a short story recall task and various word learning tests, and
the Delayed Matching To Sample Test, a measure of
visuospatial episodic memory(19,21,22,68,77,79,92). While
some of these findings are from category C studies, the
majority are from higher-graded studies(21,22,77,79).
Interestingly, some of the domain-specific nutrient effects
shown here in human RCT studies overlap quite closely
with findings reported in animal studies. For example, in rat
studies, positive effects of flavonoid intake have been shown
on spatial memory tasks(10,99) and psychomotor perform-
ance(100). In animal models, these tasks are thought to
involve brain regions such as the hippocampus, which is
associated with place learning(101), the basal ganglia and
striatum which are linked to cue and response learning(102),
and the prefrontal cortex, which is central to rule acquisition
in procedural learning(103). In rats, these same regions have
been shown to be responsive to treatment by flavonoids, for
instance via increased striatal muscarinic receptor sensi-
tivity(10,16,99,104,105). In terms of mechanisms, there is some
suggestion that flavonoids may improve cell signalling
which in turn may enhance neuroprotection through their
antioxidant and anti-inflammatory properties, and may also
promote neurogenesis. According to neuroimaging studies,
similar brain regions are involved in human tasks. For
example, areas including the hippocampal formation have
been implicated in spatial memory(48), whereas psychomo-
tor processing speed may include a striatal component(50).
Whether or not the mechanisms of action are the same in
both animals and humans remains to be seen.
Despite strong evidence from animal studies of a positive
relationship impact of certain nutrients on cognitive
function, these important findings do not appear to be
driving RCT research in human studies. In human flavonoid
research, for instance, there appears to be little explicit
reference to animal work in the search for ‘primary
dependent measures’ to use in human flavonoid intervention
studies. As an example, spatial memory was explored in
only 65 % of flavonoid studies, despite evidence from
animal work that spatial processing may be the cognitive
domain which is most sensitive to flavonoid intervention.
While only 20 % of those studies that included a task with a
spatial memory component showed positive results, it is
noteworthy that those specifically designed to measure
‘spatial working memory’ did show some nutrient-driven
improvements (see Table 2, under ‘Working memory:
visual/visuospatial’). This may have been due to the level of
cognitive demand, or to the number and complexity of
cognitive functions or processes required to perform the
task. One key difference between animal and human studies
though is that spatial tasks used in animal studies involve the
rodent subject moving within a three-dimensional space
with ever-changing environmental cues. In human studies,
spatial tasks tend to be presented in a two-dimensional
environment, arguably involving very different kinds of
cognitive functioning to those employed in animal studies.
While a number of flavonoid studies used memory tasks
with a visual or visuospatial element, few have attempted to
measure spatial working memory in a similar way to that in
which it is assessed in animal paradigms; this is particularly
true of cognitive processes and functions that are normally
employed in three-dimensional maze task environments
such as navigation and orientation. Better analogues of
animal tasks or more similarly demanding tasks should be
developed, perhaps using new technologies such as virtual
reality (see, for example, Astur et al. (106)).
While some preliminary conclusions can be drawn from
the available data, the ability to do so is hindered by an
inconsistent approach to cognitive testing in nutrition
supplementation studies, particularly in terms of the
cognitive domains measured and tasks employed. Some
researchers targeted specific domains such as memory or
executive function, whereas others measured multiple
domains. Both single and multiple domain studies included
different numbers of measures within each cognitive
domain, varying from single measures per domain to
multiple measures, and researchers treating cognitively
impaired populations were limited to using general
measures of cognitive function for ethical and/or practical
reasons. There is therefore little correspondence between
the approaches taken in the measurement of cognitive
function within or across nutrients, making it difficult to
build a comprehensive picture of the relationship between
nutrition and cognitive function.
It is also clear from looking at Table 2 that while some
cognitive domains have been covered fairly extensively, for
instance, episodic memory, others, such as semantic
memory, have not. There are also a number of key gaps in
the domains measured where no RCT research has been
carried out at all, namely implicit, procedural, and
prospective memory. Collectively, procedural memory and
implicit memory are involved in skill learning(107,108). They
are therefore important to study from a practical
perspective, particularly for every-day cognitive functioning
in older human adults, and there is strong evidence that the
striatum, previously shown to be sensitive to nutrient
supplementation in animal models(10), is involved in
procedural memory(109). Furthermore, implicit compared
with explicit memory tasks are thought to make minimal
demands on hippocampal-based brain regions(110); as many
animal studies have focused on the effects of nutrients on
cognition using tasks with a significant hippocampal
component, the inclusion of implicit memory tasks would
provide a good empirical test of the degree to which benefits
observed for particular nutrients are brain-region specific.
Prospective memory declines in older adulthood, especially
when the task makes demands on the provision and
allocation of attentional/executive resources(111), as it
recruits areas of the prefrontal cortex and parietal
cortex(112), and is also therefore worthy of exploration.
Overall, distinctions between implicit v. explicit memory,
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procedural v. declarative memory, and prospective v.
retrospective memory represent major taxonomic divisions
in human memory and cannot simply be ignored.
Another source of inconsistency comes from the wide
range of measures used across studies, in particular those
exploring the same nutrient, making comparability between
studies and within domains difficult. Not only has a large
number of tasks been used within a single domain, the
variability between those tasks is also a concern. For
instance, the verbal memory tasks varied enormously from
each other, from recall (immediate and delayed) and
recognition of word lists, paragraphs and stories to paired-
associates recall; the word lists in the memory tasks ranged
from ten to thirty words; semantic memory tasks measured
(1) naming of objects, (2) differentiation of words and non-
words, (3) similarities between nouns and (4) synonyms for
given words; and two spatial working memory tasks differed
in the type of stimuli shown and the level of complexity of
the task. So while all these tasks may be measuring
cognitive function within the same primary domain, they
may also impose different levels of cognitive demand, and
involve different processes or even different secondary
cognitive domains. One sensible approach may therefore be
to include at least two measures of a cognitive domain of
interest where possible.
One of the more concerning findings in the present review
is that researchers continue to use cognitive tests that
seemingly display little sensitivity to nutritional supplemen-
tation. The MMSE, recommended for use as a screening
tool for cognitive impairment, was used as a performance
measure in 38 % of the studies but failed to show
significance in all but one, suggesting either that the
nutrient in question has no effect on general cognitive
function, or that the MMSE is not sensitive enough to
measure short-term micronutrient- or flavonoid-driven
cognitive change. While Woo et al. (89) did find significant
positive effects of flavonoid treatment on postmenopausal
women on three cognitive tasks including the MMSE
(which may have been due to differences in baseline scores),
Cockle et al. (65) found no change using the MMSE but a
positive effect of treatment using a choice reaction time
task, which suggests that the issue here may be one of test
sensitivity rather than lack of treatment efficacy. The MMSE
may simply not be sensitive enough to capture the subtle
cognitive changes associated with dietary treatments,
particularly with younger and/or cognitively healthy
populations who are likely to perform at ceiling. Over half
the reviewed studies which used the MMSE as a
performance measure had normal populations without
dementia or mild cognitive impairment, which may also
have contributed to the large number of null findings.
Similarly, the Trail-Making Task was only significant in two
out of thirteen studies, showing a negative effect of
treatment in both cases. The Boston Naming Test was used
as a measure of semantic memory in six studies, including
two category A RCT(24,28), but was not significant in any. Of
course, such consistently negative results may suggest that
nutritional supplementation has no effect, or even a
detrimental effect, on the specific cognitive function(s)
measured by these tasks. As positive treatment effects have
been observed with other, similar tasks though, it is more
likely a question of task sensitivity and/or intensity of task
demand. The possibility of type I error and lack of power in
relation to effect size should also be considered. Therefore,
while replication of cognitive methodologies is important, it
would be good practice to move away from measures that
repeatedly show null results and to identify tasks that are
more consistently sensitive to treatment in the target
populations.
There is also considerable confusion in the literature
concerning the terms used to describe the same task. As one
example, the Trail-Making Task Parts A and B have been
referred to by different researchers as measuring visuomotor
tracking and attention(86); speed for attention, sequencing,
mental flexibility, visual search and motor function(24);
information processing and prefrontal lobe function(85);
sequencing and shifting perceptual sets, concentration/
vigilance and visuomotor scanning/tracking speed(88).
While all these terms may have some validity, this
inconsistency may lead to confusion for future researchers,
and may hinder systematic comparison and interpretation of
the specific tasks across studies. There were also
discrepancies between what tasks actually measured. For
instance, the Similarities Test was categorised by Eussen
et al. (71) as executive function, by Howes et al. (85) as verbal
reasoning(85) and as an aspect of general intelligence by
Santos et al. (91). In a number of cases, the tasks have been
listed with no description and the reader is simply referred
to the manual. This is especially true of Wechsler Adult
Intelligence Scale and Wechsler Memory Scale tasks, which
have undergone a number of updates over the years, and
researchers may not have access to particular editions.
Without access to the manuals it is often difficult to assess
the suitability and sensitivity of tasks for future research.
The focus of much of the research reviewed here
currently centres on identifying the correct dose and
duration of treatment to bring about improvements in
cognitive function, and adequately powering the study to
enable significant differences to be shown. Authors of
approximately a third of the studies reviewed suggested that
their sample sizes were too small to provide adequate
statistical power, or that their significant findings were a
result of type I error. Those who had carried out power
calculations often had to base their calculations on previous
research in another area, or on projected changes in
biomarkers rather than increments in cognitive change, due
to the lack of availability of more appropriate data. Some
authors warned that their results may not be generalisable to
other populations. While there clearly are inconsistencies of
approach in terms of intervention dose and duration, and
issues about statistical power, sample size and type I error, it
is our view that definitive conclusions regarding the efficacy
of the dose or duration of a particular nutrient cannot be
made until the sensitivity of the cognitive measures used has
been established for the type of nutrient under investigation.
This may be achievable through, for instance, the systematic
manipulation of cognitive demand in an acute design, as
seen in the glucose RCT study literature, where glucose was
shown to be of greater benefit on more cognitively
demanding tasks(98,113).
Further consideration of individual differences such as
age needs to be given when selecting cognitive tests.
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For example, as can be seen from Table 1, less than a quarter
of the studies were carried out on younger adults. As it is
possible that the optimal window of opportunity for slowing
or reversal of age-related declines by dietary means may
occur much earlier in the life cycle, younger populations
should be given greater consideration. Clearly tests such as
the MMSE are unlikely to be sensitive enough for younger,
healthier populations, but tasks that are more challenging
and sensitive for younger participants will also inform about
older cognitively intact and/or at-risk populations, allow
better comparability between young and older age groups,
and enable a greater understanding of diet-related cognitive
evolution throughout the lifespan. Screening is important, as
there is a danger of including participants with mild
cognitive impairment within a healthy study sample, which
makes interpretation difficult, as results may not be
transferable to cognitively healthy populations. Finally,
reporting of statistical differences in cognitive scores at
baseline is essential, as this enables an informed assessment
of parity between treatment groups based on initial
cognitive performance.
Conclusion and recommendations
Research on the relationship between nutrition and
cognitive function clearly has a long way to go, and an
increasingly complex picture is emerging. Findings from
epidemiological, longitudinal, observational and animal
studies suggest that certain nutrients may offer great
potential in the treatment of age-related cognitive disorders,
and excitingly, certain nutrients may have specific roles to
play in improving specific cognitive functions. However,
this potential is currently hampered by methodological
difficulties, and by the unsystematic approach being adopted
across studies, reducing their comparability and making
interpretation of findings difficult. As well as interpretative
difficulties, such a ‘scattergun’ approach limits the ability to
make reliable comparisons across studies. The above
findings demonstrate the necessity for more standardised,
sensitive, and theory-derived sets of cognitive tasks in future
clinical and dietary intervention studies.
The present review offers a number of implications for
future chronic dietary studies. Firstly, there is a clear need to
pay closer attention to animal studies and to previous human
work when identifying appropriate cognitive tests, both
within and across nutrients. Where reliable and nutritionally
sensitive cognitive tasks are identified, researchers should
endeavour to incorporate them into subsequent test batteries
so that patterns relating to issues such as dose–response
effects and nutrient type sensitivity can more easily emerge.
Secondly, tasks need to be appropriate to the target
population, be sufficiently sensitive to the nutrient under
investigation, be sufficiently demanding to discriminate
between good and poor performers, and capable of avoiding
ceiling (and floor) effects. Thirdly, greater care should be
taken to avoid statistical artifacts likely to bring about null
findings, such as lack of power, and type I errors. Finally,
including more than a single task within a domain (for
example, two executive function tasks) would greatly help
to determine whether a null effect for a particular nutrient is
a real finding or reflects a lack of task sensitivity to the
nutrient in question. Adopting these simple guidelines will
bring much needed clarity and methodological rigour
and, in the longer term, permit researchers to make much
clearer policy recommendations for dietary intake in the
general public.
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